Atara Biotherapeutics price to book ratio ATRA

Market value divided by the book value of the company's net assets, since 2015.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 17.0×; Oct 2023
10-year median: 2.9×
10-year range: 1.2× to 28.3×
Peer median: 1.9×

Atara Biotherapeutics' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Oct 2023, at 17.0×.

On the days it had one over the last ten years, its median was 2.9×, from 1.2× in Sep 2022 to 28.3× in Aug 2023.

Price to book ratio over time

median 2.9×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	17.0×	1.8×	28.3×
2022	1.7×	1.2×	4.6×
2021	4.5×	2.4×	5.2×
2020	4.3×	1.5×	5.4×
2019	2.8×	2.1×	5.4×
2018	3.9×	2.7×	9.6×
2017	2.7×	1.4×	2.7×
2016	1.5×	1.3×	2.4×
2015	2.3×	2.0×	14.1×

Against its peers

Companies in Healthcare nearest Atara Biotherapeutics' size, closest first, today.

Company	Price to book ratio
ATRAAtara Biotherapeutics	n/m
ICCCImmucell	3.0×
KEQUKewaunee Scientific	1.3×
LFVNLifevantage	2.2×
SPROSpero Therapeutics	1.5×
APTAlpha Pro Tech	0.9×
ATNMActinium Pharmaceuticals	1.6×
NEPHNephros	3.2×
PDEXPro DEX	4.2×
PLXProtalix BioTherapeutics	2.9×
NATRNatures Sunshine Products	1.3×
Peer median	1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Atara Biotherapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.